PMID- 33473191
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20230129
IS  - 2042-0226 (Electronic)
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 18
IP  - 3
DP  - 2021 Mar
TI  - HLA class I loss in colorectal cancer: implications for immune escape and 
      immunotherapy.
PG  - 556-565
LID - 10.1038/s41423-021-00634-7 [doi]
AB  - T cell-mediated immune therapies have emerged as a promising treatment modality 
      in different malignancies including colorectal cancer (CRC). However, only a 
      fraction of patients currently respond to treatment. Understanding the lack of 
      responses and finding biomarkers with predictive value is of great importance. 
      There is evidence that CRC is a heterogeneous disease and several classification 
      systems have been proposed that are based on genomic instability, immune cell 
      infiltration, stromal content and molecular subtypes of gene expression. Human 
      leukocyte antigen class I (HLA-I) plays a pivotal role in presenting processed 
      antigens to T lymphocytes, including tumour antigens. These molecules are 
      frequently lost in different types of cancers, including CRC, resulting in tumour 
      immune escape from cytotoxic T lymphocytes during the natural history of cancer 
      development. The aim of this review is to (i) summarize the prevalence and 
      molecular mechanisms behind HLA-I loss in CRC, (ii) discuss HLA-I expression/loss 
      in the context of the newly identified CRC molecular subtypes, (iii) analyze the 
      HLA-I phenotypes of CRC metastases disseminated via blood or the lymphatic 
      system, (iv) discuss strategies to recover/circumvent HLA-I expression/loss and 
      finally (v) review the role of HLA class II (HLA-II) in CRC prognosis.
FAU - Anderson, Per
AU  - Anderson P
AD  - Instituto de Investigacion Biosanitaria (ibs.GRANADA), Granada, Spain.
AD  - Servicio de Analisis Clinicos e Inmunologia, Hospital Universitario Virgen de las 
      Nieves, 18014, Granada, Spain.
FAU - Aptsiauri, Natalia
AU  - Aptsiauri N
AD  - Instituto de Investigacion Biosanitaria (ibs.GRANADA), Granada, Spain.
AD  - Departamento de Bioquimica, Biologia Molecular 3 e Inmunologia, Universidad de 
      Granada, Granada, Spain.
FAU - Ruiz-Cabello, Francisco
AU  - Ruiz-Cabello F
AD  - Instituto de Investigacion Biosanitaria (ibs.GRANADA), Granada, Spain.
AD  - Servicio de Analisis Clinicos e Inmunologia, Hospital Universitario Virgen de las 
      Nieves, 18014, Granada, Spain.
AD  - Departamento de Bioquimica, Biologia Molecular 3 e Inmunologia, Universidad de 
      Granada, Granada, Spain.
FAU - Garrido, Federico
AU  - Garrido F
AD  - Instituto de Investigacion Biosanitaria (ibs.GRANADA), Granada, Spain. 
      federico.garrido.sspa@juntadeandalucia.es.
AD  - Servicio de Analisis Clinicos e Inmunologia, Hospital Universitario Virgen de las 
      Nieves, 18014, Granada, Spain. federico.garrido.sspa@juntadeandalucia.es.
AD  - Departamento de Bioquimica, Biologia Molecular 3 e Inmunologia, Universidad de 
      Granada, Granada, Spain. federico.garrido.sspa@juntadeandalucia.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210120
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Animals
MH  - Colorectal Neoplasms/*immunology/pathology/therapy
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - *Tumor Escape
PMC - PMC8027055
OTO - NOTNLM
OT  - Colorectal cancer
OT  - HLA Class I
OT  - Immune escape
COIS- The authors declare no competing interests.
EDAT- 2021/01/22 06:00
MHDA- 2021/12/28 06:00
PMCR- 2022/03/01
CRDT- 2021/01/21 05:31
PHST- 2020/10/15 00:00 [received]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2021/01/21 05:31 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - 10.1038/s41423-021-00634-7 [pii]
AID - 634 [pii]
AID - 10.1038/s41423-021-00634-7 [doi]
PST - ppublish
SO  - Cell Mol Immunol. 2021 Mar;18(3):556-565. doi: 10.1038/s41423-021-00634-7. Epub 
      2021 Jan 20.